<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2811211381
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CANDAN 16 mg tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CANDESARTAN CILEXETIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        45.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="(Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            (Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 437]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Middle East Pharmaceutical Industries Co Ltd Avalon Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>CANDAN tablet called (‛CANDAN&rsquo; in this leaflet), is contains the active substance candesartan which belongs to a<br />group of medicines known as angiotensin II receptor antagonists that lower blood pressure. It works by making your<br />blood vessels relax and widen (which helps to lower your blood pressure). It also makes it easier for your heart to pump<br />blood to all parts of your body.<br />CANDAN is used for:<br />&bull; treating high blood pressure (hypertension) in all grades.<br />&bull; treating heart failure and impaired left ventricular systolic function and as additional therapy to Angiotensin Converting<br />Enzyme (ACE) inhibitors or when ACE inhibitors are not tolerated.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take CANDAN<br />if you are allergic to candesartan cilexetil or any of the other ingredients of this medicine (listed in section 6).<br />&bull; if you have severe liver disease or biliary obstruction (a problem with the drainage of the bile from the gall bladder).<br />&bull; if you are more than 3 months pregnant. (It is also better to avoid CANDAN in early pregnancy - see pregnancy section).<br />&bull; if the patient is a child under 1 year of age.<br />&bull; if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing<br />aliskiren.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking CANDAN:<br />&bull; if you have heart, liver or kidney problems, or are on dialysis<br />&bull; if you have recently had a kidney transplant<br />&bull; if you are vomiting, have recently had severe vomiting, or have diarrhoea<br />&bull; if you have a disease of the adrenal gland called Conn&rsquo;s syndrome (also called primary hyperaldosteronism)<br />&bull; if you have low blood pressure<br />&bull; if you have ever had a stroke<br />&bull; if you are taking any of the following medicines used to treat high blood pressure:<br />- an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems<br />- aliskiren<br />&bull; if you are taking an ACE-inhibitor together with a medicine which belongs to the class of medicines known as mineralocorticoid<br />receptors antagonists (MRA). These medicines are for the treatment of heart failure (see &ldquo;Other medicines<br />and CANDAN&rdquo;)<br />&bull; you must tell your doctor if you think you are (or might become) pregnant. CANDAN is not recommended in early<br />pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if<br />used at that stage (see pregnancy section).<br />Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your<br />blood at regular intervals.<br />See also information under the heading &ldquo;Do not take CANDAN&rdquo;<br />If you are going to have an operation, tell your doctor or dentist that you are taking CANDAN. This is because candesartan,<br />when combined with some anaesthetics, may cause a drop in blood pressure.<br />Children and adolescents<br />CANDAN has been studied in children. For more information, talk to your doctor. CANDAN must not be given to children<br />under 1 year of age due to the potential risk to the developing kidneys.<br />Other medicines and CANDAN<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines<br />obtained without a prescription.<br />CANDAN can affect the way some other medicines work, and some medicines can have an effect on CANDAN. Your<br />doctor may need to change your dose and/or to take other precautions. If you are using certain medicines, your doctor<br />may need to do blood tests from time to time. In particular, tell your doctor if you are taking any of the following medicines:<br />&bull; Other medicines to help lower your blood pressure, including beta-blockers, diazoxide, ACE-inhibitors (such as enalapril,<br />captopril, lisinopril or ramipril) or aliskiren (see also information under the headings &ldquo;Do not take CANDAN&rdquo; and<br />&ldquo;Warnings and precautions&rdquo;).<br />&bull; An ACE-inhibitor together with certain other medicines to treat your heart failure, which are known as mineralocorticoid<br />receptors antagonists (MRA) (for example spironolactone, eplerenone).<br />&bull; Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, diclofenac, celecoxib, or etoricoxib<br />(medicines used to relieve pain and inflammation).<br />&bull; Acetylsalicylic acid (if you are taking more than 3 g each day) (medicine to relieve pain and inflammation).<br />&bull; Potassium supplements or salt substitutes containing potassium (medicines that increase the amount of potassium<br />in your blood).<br />&bull; Heparin (a medicine for thinning the blood)<br />&bull; Diuretics (medicines known as &lsquo;water tablets&rsquo;)<br />&bull; Lithium (a medicine used to treat mental health problems)<br />CANDAN with food and drink<br />&bull; You can take CANDAN with or without food.<br />&bull; When you are prescribed CANDAN discuss with your doctor before drinking alcohol. Alcohol, while taking CANDAN,<br />may make you feel faint and dizzy.<br />Pregnancy and breastfeeding<br />Pregnancy<br />If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice<br />before taking this medicine. Your doctor will normally advise you to stop taking CANDAN before you become pregnant or<br />as soon as you know you are pregnant and will advise you to take another medicine instead of this medicine. CANDAN<br />is not recommended in early pregnancy and must not be taken when more than 3 months pregnant, as it may cause<br />serious harm to your baby if used after the third month of pregnancy.<br />Breast-feeding<br />If you are breast-feeding or about to start breast-feeding, ask your doctor or pharmacist for advice before taking this medicine.<br />CANDAN is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment<br />for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.<br />Driving and using machines<br />Some people may feel tired or dizzy when taking this medicine. If this happens to you, do not drive or use any tools<br />or machines.<br />CANDAN contains lactose<br />If you have been told by your doctor that you have an intolerance to some sugars, such as lactose, contact your doctor<br />before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This is a long-term treatment.<br />Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you<br />are not sure. It is important to keep taking CANDAN every day.<br />You can take CANDAN with or without food. Swallow the tablet with a drink of water. Try to take the tablet at the same<br />time each day. This will help you remember to take it.<br />The tablet cannot be divided into equal doses.<br />To treat high blood pressure:<br />The recommended starting dose is 8 mg once a day. Your doctor may increase this dose up to 32 mg once a day<br />depending on blood pressure response.<br />In some patients, such as those with liver problems, kidney problems or those who recently have lost body fluids, e.g.</p><p>through vomiting or diarrhoea or by using water tablets, the doctor may prescribe a lower starting dose.<br />Some black patients may have a reduced response to this type of medicine when given as the only treatment; these<br />patients may need a higher dose.<br />To treat heart failure:<br />The recommended starting dose of candesartan is 4 mg once a day. Your doctor may increase your dose by doubling<br />the dose at intervals of at least 2 weeks up to 32 mg once a day. CANDAN can be taken together with other medicines<br />for heart failure, and your doctor will decide which treatment is suitable for you.<br />Use in children and adolescents with high blood pressure:<br />Children 6 to 18 years of age:<br />The recommended starting dose is 4 mg once daily.<br />For patients weighing less than 50 kg your doctor may decide the dose needs to be increased to a maximum of 8 mg<br />once daily.<br />For patients weighing 50 kg or more your doctor may decide the dose needs to be increased to 8 mg once daily and<br />then to 16 mg once daily, if needed.<br />If you use more CANDAN than you should<br />If you take more CANDAN than prescribed by your doctor, contact a doctor or pharmacist immediately for advice. Your<br />blood pressure may become low and you may feel dizzy<br />If you forget to use CANDAN<br />If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule. Do<br />not take a double dose to make up for a forgotten dose.<br />If you stop using CANDAN<br />If you stop taking this medicine, your blood pressure may increase again. Therefore, do not stop taking CANDAN without<br />talking to your doctor first.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Stop taking CANDAN and contact your doctor or go to the nearest hospital emergency department if you have<br />any of the following:<br />Very rare (may affect less than 1 in 10,000 people):<br />&bull; swelling of the face, lips, tongue and/or throat, which may cause difficulties in breathing or swallowing.<br />&bull; an increase in the number of infections you may get which causes fever, severe chills, sore throats, mouth ulcers or<br />chesty coughs. These may be due to a low number of white blood cells.<br />&bull; abnormal liver function including inflammation of the liver (hepatitis) which may be seen as feeling sick (nausea), being<br />sick (vomiting) loss of appetite, generally feeling unwell, fever itching, yellowing of the skin or whites of the eyes with pale<br />stools or dark coloured urine. These may be signs of serious problems with your liver.<br />&bull; a decrease in kidney function which may be seen as producing little or no urine, cloudy urine or blood in the urine,<br />pain when passing urine or lower back pain. These may be signs of serious kidney problems. In very rare cases kidney<br />failure may occur.<br />Other possible side effects include:<br />Common (may affect up to 1 in 10 people):<br />&bull; feeling dizzy/spinning sensation when standing still (vertigo)<br />&bull; headache<br />&bull; chest infection<br />&bull; low blood pressure. This may make you feel faint or dizzy<br />&bull; an increased amount of potassium in your blood which can be seen in a blood test, especially if you already have<br />kidney problems or heart failure. If this is severe you may notice tiredness, weakness, an irregular heartbeat or pins<br />and needles in your hands or feet<br />Very rare (may affect less than 1 in 10,000 people):<br />&bull; skin rash, lumpy rash (hives)<br />&bull; itching<br />&bull; cough<br />&bull; back pain, pain in joints and muscles<br />&bull; feeling sick (nausea)<br />&bull; changes in blood test results such as a reduced amount of sodium or an increase in liver enzymes in your blood.<br />Not known (frequency cannot be estimated from the available data):<br />&bull; diarrhoea<br />Additional side effects seen in children and adolescents<br />In children treated for high blood pressure, side effects appear to be similar to those seen in adults, but they happen<br />more often. A sore throat is a very common side effect seen in children and a blocked or runny nose, fever and increased<br />heart rate are common side effects in children but none of these have been reported in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children.<br />&bull; Store below 30&deg;C.<br />&bull; Do not use this medicine after the expiry date which is stated on the label and carton. The expiry date refers to the<br />last day of that month.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines<br />if you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What CANDAN contains<br />&bull; The active substance is candesartan cilexetil. Each tablet contains either 8mg or 16mg of candesartan cilexetil.<br />&bull; The other ingredients are: Lactose Monohydrate, Maize Starch, Red iron oxide, Hydroxypropyl Cellulose, Polyethylene<br />Glycol, Carboxymethyl Cellulose Calcium and Magnesium Stearate.<br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CANDAN available in 8 mg tablets and 16 mg tablets. The tablets are described below:
CANDAN 8 mg tablets are pink, biconvex, round tablet, debossed with “8” on one side and plain on other side.
CANDAN 16 mg tablets are Pink, compact, biconvex, round, engraved on one side with code
C31 and scored another side.
CANDAN 8 mg and 16 mg are packed in 2 blisters (14tablets / blister).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Middle East Pharmaceutical Industries Co Ltd (Avalon Pharma)<br />P.O.Box 4180 Riyadh 11491<br />2nd Industrial City, Riyadh, Kingdom of Saudi Arabia<br />Tel: +966 (11) 2653948 -2653427<br />Fax: +966 (11) 2654723</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تحتوي أقراص كاندان تُدعى ) &laquo;كاندان &raquo; في هذه النشرة( على المادة الفعالة كانديسارتان التي تنتمي لمجموعة من الأدوية تُعرف باسم حاصرات مستقبلات<br />أنجيوتنسين 2 ، والتي تعمل على خفض ضغط الدم. تساعد هذه المادة على استرخاء وتوسيع الأوعية الدموية )مما يساعد على خفض ضغط الدم(. كما تُسهل<br />على القلب ضخ الدم إلى جميع أجزاء الجسم.<br />يُستخدم كاندان في:<br />&bull; علاج ضغط الدم المرتفع )فرط ضغط الدم( بجميع درجاته.<br />&bull; علاج قصور القلب، وضعف وظائف البطين الأيسر الانقباضية، وكعلاج إضافي لمثبطات الإنزيم المحول للأنجيوتنسين أو عندما لا يُمكن للشخص تحمُّل<br />مثبطات الإنزيم المحول للأنجيوتنسين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول كاندان في الحالات التالية:<br />&bull; إذا كنت تعاني من الحساسیة من كانديسارتان سيليكسيتيل أو أي من المكونات الأخرى لهذا الدواء )الموضحة في القسم 6(.<br />&bull; إذا كنت تعاني من مرض كبدي حاد أو انسداد في القنوات الصفراوية )مشكلة في تصريف الصفراء من المرارة(.<br />&bull; إذا كنتِ حاملً منذ أكثر من 3 أشهر. )من الأفضل كذلك أن يتم تجنُّب كاندان خلال الفترة المبكرة من الحمل- راجع القسم الخاص بالحمل(.<br />&bull; إذا كان المريض طفلً يقل عمره عن عامٍ واحد.<br />&bull; إذا كنت تعاني من مرض السكري أو من قصورٍ في وظائف الكلى، ويتم علاجك بدواء لخفضِ ضغط الدم يحتوي على الأليسكيرين .<br />تحذيرات واحتياطات<br />تحدث مع الطبيب أو الصيدلي قبل تناول كاندان في الحالات التالية:<br />&bull; إذا كانت لديك مشاكل في القلب أو الكبد أو الكلى أو كنت تداوم على الغسيل الكلوي.<br />&bull; إذا خضعت مؤخراً لعملية زرع كلى.<br />&bull; إذا كنت تتقيأ أو عانيت مؤخراً من قيء شديد أو إذا كنت تعاني من الإسهال.<br />&bull; إذا كنت تعاني من مرض في الغدة الكظرية يسمى متلازمة كون )وتسمى أيضًا بفرط الألدوستيرونية البدئية(.<br />&bull; إذا كان ضغط دمك منخفضًا.<br />&bull; إذا كنت قد أصبت من قبل بسكتة دماغية.<br />&bull; إذا كنت تتناول أيًّا من الأدوية التالية التي تُستخدم في علاج ضغط الدم المرتفع:<br />- مثبطات الإنزيم المحول للأنجيوتنسين، على سبيل المثال: )إنالابريل وليزينوبريل وراميبريل(، خاصة إذا كنت تعاني من مشاكل في الكلى مرتبطة<br />بمرض السكري.<br />- أليسكيرين<br />&bull; إذا كنت تتناول أحد مثبطات الإنزيم المحوّل للأنجيوتنسين مع دواء ينتمي إلى فئة من الأدوية معروفة باسم مضادات مستقبلات القشرانيات المعدنية. تُستخدم<br />تلك الأدوية في علاج قصور القلب )راجع &laquo;الأدوية الأخرى وكاندان .)&raquo;<br />&bull; يجب أن تُخبري طبيبك إذا كنتِ تظنين أنك حاملٌ )أو أنك قد تصبحين حاملً(. لا يُنصح باستخدام كاندان خلال المراحل المبكرة من الحمل، وبجب عدم<br />تناوله إذا كنتِ حاملً منذ أكثر من 3 أشهر؛ حيث قد يسبب أضرارًا خطيرة للجنين إذا تم استخدامه خلال تلك المرحلة )أنظري القسم الخاص بالحمل(.<br />قد يقوم طبيبك بفحص وظائف الكلى وضغط الدم وكمية الالكترولايت، على سبيل المثال: )البوتاسيوم( في دمك على فترات زمنية منتظمة.<br />راجع أيضًا المعلومات الموجودة تحت عنوان &laquo;لا تتناول كاندان في الحالات التالية .&raquo;<br />إذا كنت ستُجري عملية جراحية فأخبر طبيبك أو طبيب الأسنان أنك تتناول كاندان؛ حيث قد يُسبب الكانديسارتان عند دمجه مع بعض أدوية التخدير انخفاضًا<br />في ضغط الدم.<br />الأطفال والمراهقون<br />تمت دراسة تأثير كاندان على الأطفال. لمعرفة المزيد من المعلومات استشر الطبيب. يجب عدم إعطاء كاندان للأطفال الأقل من عام واحد بسبب خطره<br />على نمو الكلى.<br />الأدوية الأخرى وكاندان<br />أخبر طبيبك أو الصيدلي عما إذا كنت تتناول أو تناولتَ مؤخرًا أو قد تتناول أي أدوية أخرى، بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية.<br />يمكن لكاندان أن يؤثر على الطريقة التي تعمل بها بعض الأدوية الأخرى، ويمكن لبعض الأدوية أن تؤثر على كاندان.<br />قد يحتاج طبيبك لتغيير الجرعة و/ أو لاتخاذ احتياطات أخرى. إذا كنت تتناول أدوية معينة فقد يحتاج طبيبك لإجراء تحاليل للدم من وقت لآخر. أخبر الطبيب<br />إذا كنت تتناول أيًّا من الأدوية التالية على وجه الخصوص:<br />&bull; الأدوية الأخرى التي تُساعد على خفض ضغط الدم، بما في ذلك حاصرات مستقبلات بيتا والديازوكسيد ومثبطات الإنزيم المحوّل للأنجيوتنسين، مثل: )إنالابريل<br />وكابتوبريل وليزينوبريل وراميبريل(، أليسكيرين )راجع أيضًا المعلومات الموجودة تحت العناوين &laquo;لا تتناول كاندان &raquo; و &laquo;التحذيرات والاحتياطات .)&raquo;<br />&bull; أحد مثبطات الإنزيم المحوّل للأنجيوتنسين مع دواء ينتمي إلى فئة من الأدوية معروفة باسم مضادات مستقبلات القشرانيات المعدنية، على سبيل المثال:<br />)سبيرونولاكتون و إبليرينون(.<br />&bull; مضادات الالتهاب غير الستيرويدية مثل: إيبوبروفين، أو نابروكسين، أو ديكلوفيناك، أوسيليكوكسيب، أو إيتوريكوكسيب )الأدوية المستخدمة لتخفيف الألم<br />والالتهابات(.<br />&bull; حمض أسيتيل الساليسيليك )إذا كنت تتناول أكثر من 3 غرام كل يوم( )دواء لتخفيف الألم والالتهاب(.<br />&bull; مكملات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم )الأدوية التي تزيد من كمية البوتاسيوم في الدم(.<br />&bull; الهيبارين )دواء لسيولة الدم(.<br />&bull; مدرات البول )الأدوية المعروفة باسم &laquo;أقراص الماء .)&raquo;<br />&bull; الليثيوم )دواء يستخدم لعلاج مشاكل الصحة العقلية(.<br />كاندان مع الطعام والشراب<br />&bull; يمكنك تناول كاندان مع الطعام أو بدونه.<br />&bull; عندما يُوصف لك كاندان؛ تناقش مع طبيبك قبل شرب الكحول. قد يجعلك الكحول تشعر بالإغماء والدوار أثناء تناول كاندان.<br />الحمل والرضاعة الطبيعيَّة<br />الحمل<br />استشيري الطبيب أو الصيدلي إذا كنتِ حاملً أو تعتقدين أنك قد تكونين حاملً أو تخُططين لحمل. سوف ينصحك طبيبك في العادة بالتوقف عن تناول كاندان قبل<br />أن تحملين، أو بمجرد معرفتك بوجود حمل، وسوف ينصحك بتناول دواء آخر بدلً من هذا الدواء. لا يُنصح باستخدام كاندان خلال المراحل المبكرة من الحمل،<br />ويجب عدم تناوله إذا كنتِ حاملً منذ أكثر من 3 أشهر؛ حيث قد يسبب أضرارًا خطيرة للجنين إذا تم استخدامه بعد الشهر الثالث من الحمل.<br />الرضاعة الطبيعية<br />إذا كنتِ تقومين بالرضاعة الطبيعية أو على وشك بدء الرضاعة الطبيعية؛ استشيري الطبيب أو الصيدلي قبل تناول هذا الدواء. لا يُنصح باستخدام كاندان<br />من قبل الأمهات اللاتي يُمارسن الرضاعة الطبيعية، قد يختار لك طبيبك علاجًا آخر إذا كنتِ ترغبين في ممارسة الرضاعة الطبيعية، خاصة إذا كان طفلك<br />حديث الولادة أو خديج.<br />القيادة واستخدام الآلات<br />قد يشعر بعض الأشخاص بالتعب أو الدوار عند تناول هذا الدواء. إذا حدث ذلك لك فلا تقم بالقيادة ولا تستخدم أيَّ أدوات أو آلات.<br />كاندان يحتوي على اللاكتوز<br />إذا أخبرك طبيبك أن لديك حساسية تجاه بعض أنواع السكريات، مثل: )اللاكتوز(، فاتصل بطبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>هذا العلاج طويل الأجل.<br />تناول هذا الدواء دائمًا طبقًا لإرشادات الطبيب أو الصيدلي. يجب مراجعة طبيبك أو الصيدلي إذا لم تكن متأكدًا. من الضروري أن تستمر في تناول كاندان يومياً.<br />يُمكنك تناول كاندان مع الطعام أو بدونه. ابتلع القرص مع شرب الماء. حاول تناول القرص في نفس الوقت يومياً. سوف يُساعدك ذلك على أن تتذكر تناوله.<br />لا يُمكن تقسيم القرص إلى جرعتين متساويتين.<br />لعلاج ضغط الدم المرتفع:<br />جرعة البداية التي يُنصح بها هي 8 ملغم مرة واحدة يومياً. قد يقوم طبيبك بزيادة تلك الجرعة إلى 32 ملغم مرة واحدة يومياً اعتمادًا على استجابة ضغط دمك.<br />بالنسبة لبعض المرضى، مثل: المرضى الذين يُعانون من مشاكل في الكبد أو مشاكل في الكلى أو الذين تعرضوا مؤخرًا لفقد سوائل الجسم، على سبيل المثال:<br />بسبب القيء أو الإسهال أو استخدام أقراص الماء، فقد يصف الطبيب جرعة أقل للبداية.<br />قد يستجيب بعض المرضى من العرق الأسود بصورة أقل لهذا النوع من الأدوية عند إعطائهم الدواء كعلاجٍ وحيد؛ قد يحتاج هؤلاء المرضى إلى جرعة أعلى.<br />لعلاج قصور القلب:<br />جرعة البداية التي يُنصح بها من كانديسارتان هي 8 ملغم مرة واحدة يوميًّا. قد يقوم طبيبك بزيادة جرعتك عن طريق مضاعفتها بفاصل زمنيٍّ لا يقل عن<br />أسبوعين لتصل إلى 32 ملغم مرة واحدة يوميًّا. يُمكن تناول كانديسارتان مع الأدوية الأخرى التي تُعالج قصور القلب، وسوف يقرر طبيبك العلاج المناسب لك.</p><p>الاستخدام لدى الأطفال والمراهقين الذين يُعانون من ارتفاع ضغط الدم:<br />الأطفال من عمر 6 إلى 18 عامًا:<br />جرعة البداية التي يُنصح بها هي 4 ملغم مرة واحدة يومياً.<br />بالنسبة للمرضى الذين يقل وزنهم عن 50 كلغ، قد يقرر طبيبك زيادة الجرعة إلى 8 ملغم بحدٍ أقصى.<br />بالنسبة للمرضى اللذين وزنهم 50 كلغ فأكثر، قد يقرر طبيبك زيادة الجرعة إلى 8 ملغم مرة واحدة يومياً، ثم إلى 16 ملغم مرة واحدة يومياً عند الحاجة.<br />إذا تناولت كاندان أكثر مما ينبغي<br />إذا تناولت كاندان أكثر مما وصفه لك طبيبك؛ اتصل بالطبيب أو الصيدلي فوراً للحصول على المشورة. قد ينخفض ضغط دمك وقد تشعر بالدوار.<br />إذا نسيت تناول كاندان<br />إذا نسيت تناول الجرعة في الوقت المحدد فتناولها في أقرب وقتٍ ممكنٍ، ثم عد مرة أخرى لجدول جرعاتك المعتاد. لا تتناول جرعة مزدوجة لتعويض<br />الجرعة المنسية.<br />إذا توقَّفت عن تناول كاندان<br />إذا توقفت عن تناول هذا الدواء فقد يرتفع ضغط دمك مرة أخرى. لذلك لا تتوقف عن تناول كاندان قبل أن تتحدث إلى طبيبك أولً.<br />إذا كانت لديك المزيد من الأسئلة بخصوص استخدام هذا الدواء، استشر الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية قد يُسبب هذا الدواء بعض الآثار الجانبية، على الرغم من أن ذلك لا يحدث مع الجميع.<br />إذا شعرت بأيٍ مما يلي توقف عن تناول كاندان، واتَّصل بطبيبك ،أو توجه إلى قسم الطوارئ في أقرب مستشفى:<br />نادرة جداً )قد تصيب أقل من 1 من كل 10.000 شخص(:<br />&bull; تورُّم الوجه أو الشفتين أو اللسان أو الحلق، الذي قد يسبب صعوبات في التنفس أو البلع.<br />&bull; زيادة في معدل الإصابة بالعدوى، والتي تسبب الحمى، والقشعريرة الشديدة، والتهاب الحلق، وتقرُّحات الفم أو السعال الصدري. قد يكون السبب في ذلك<br />هو انخفاض عدد خلايا الدم البيضاء.<br />&bull; وظائف الكبد غير الطبيعية، بما في ذلك التهاب الكبد الذي قد يظهر في صورة شعور بالتعب )الغثيان(، أو المرض )القيء(، أو فقدان الشهية، أو شعورعامٍ<br />بالتوعُّك أو حمى مصحوبة بالحكة أو اصفرار الجلد أو بياض العين مع براز فاتح أو بول داكن اللون. قد تكون هذه علامات على مشاكل خطيرة في الكبد.<br />&bull; انخفاض في وظائف الكلى الذي قد يظهر في صورة إنتاج القليل من البول أو عدم إنتاج البول، أو تعكُّر البول أو وجود دم في البول أو ألم عند التبول أو آلام<br />أسفل الظهر. قد تكون هذه علامات على مشاكل خطيرة في الكلى. في حالات نادرة جداً قد يحدث فشل كلوي.<br />تتضمن الأعراض الجانبية المحتملة الأخرى ما يلي:<br />شائعة )قد تصيب 1 من كل 10 أشخاص(:<br />&bull; الشعور بالدوار/ الإحساس بالدوران عند الوقوف بثبات )الدوخة(.<br />&bull; الصداع.<br />&bull; عدوى الصدر.<br />&bull; انخفاض ضغط الدم. قد يجعلك هذا تشعر بالإغماء أو بالدوار.<br />&bull; زيادة في كمية البوتاسيوم في الدم الذي يُمكن رؤيته في اختبارات الدم، خاصة إذا كنت تعاني بالفعل من مشكلات في الكلى أو قصور في القلب. إذا كان النقص<br />شديدًا قد تشعر بالتعب أو الضعف أو عدم انتظام ضربات القلب أو بالوخز في اليدين أو القدمين.<br />نادرة جدًّا )قد تصيب 1 من كل 10,000 شخص(:<br />&bull; طفح جلدي، طفح جلدي متكتل )شرى(.<br />&bull; حكة.<br />&bull; سعال.<br />&bull; آلام في الظهر وآلام المفاصل والعضلات.<br />&bull; الشعور بالغثيان.<br />&bull; تغيرات في نتائج اختبارات الدم على صورة انخفاض في كمية الصوديوم أو زيادة في إنزيمات الكبد في الدم.<br />غير معروفة )لا يُمكِن تقدير مدى تكرارها من البيانات المتاحة(:<br />&bull; الإسهال.<br />أعراض جانبية إضافية ظهرت لدى الأطفال والمراهقين<br />بالنسبة للأطفال الذين عولجوا من ارتفاع ضغط الدم؛ فإن الآثار الجانبية تبدو مشابهة لتلك التي تظهر عند البالغين، ولكنها تتكرر بصورة أكبر. يُعتبر التهاب<br />الحلق عرضًا جانبيا شائعًا جداً عند الأطفال، كما أن انسداد الأنف أو سيلانه والحمى وزيادة معدل ضربات القلب من الآثار الجانبية الشائعة لدى الأطفال، ولكن<br />لم يتم الإبلاغ عن أيٍّ من هذه الآثار الجانبية لدى البالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يُحفظ هذا الدواء بعيدًا عن متناول ومرأى الأطفال.<br />&bull; يُحفظ في درجة حرارة أقل من 30 درجة مئوية.<br />&bull; لا تستخدم هذا الدواء بعد تاريخ الانتهاء المُوضح على المُلصق والعلبة الكرتونية. يُشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.<br />&bull; يجب عدم التخلص من الأدوية عن طريق مياه الصرف الصحي أو ضمن النفايات المنزلية. استشر الصيدلي حول كيفية التخلص من الأدوية التي لم تعد في<br />حاجة إليها. تساعد تلك الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المادة الفعالة هي كانديسارتان سيليكسيتيل. يحتوي كل قرصٍ إما على 8 ملغم أو 16 ملغم من كانديسارتان سيليكسيتيل.<br />&bull; المكونات الأخرى هي: مونوهيدرات اللاكتوز، ونشا الذرة، وأكسيد الحديد الأحمر، وهيدروكسي بروبيل السليلوز، وبولي إيثيلين جلايكول، وكاربوكسي<br />مثيل سللوز الكالسيوم وستيرات المغنسيوم.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كيف يبدو كاندان، وما هي محتويات العبوة؟<br />كاندان متاح في صورة أقراص 8 ملغم و 16 ملغم. تُوصف الأقراص بما يلي:<br />أقراص كاندان 8 ملغم هي أقراص ورديَّة مستديرة ثنائيَّة التحدُّب، منقوش عليها رقم 8 من أحد الجانبين، وخالية من النقوش على الجانب الآخر.<br />أقراص كاندان 16 ملغم هي أقراص ورديَّة مستديرة ثنائيَّة التحدُّب، محفور على أحد الجانبين الكود C31 ، ومخدوشة على الجانب الآخر.<br />كاندان 8 ملغم و 16 ملغم مُعبَّأة في شريطين ) 14 قرصًا في كل شريط(.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة المُصنِعة وحامل تفويض التسويق<br />شركة الشرق الأوسط للصناعات الدوائية المحدودة. )أفالون فارما(<br />ص.ب. 4180 الرياض 11491<br />المدينة الصناعية الثانية، الرياض، المملكة العربية السعودية<br />هاتف 3427 265 &ndash; 3948 265 ) 11 ( 966 00<br />فاكس 4723 265 ) 11 ( 966 00</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CANDAN 8 mg tablet
CANDAN 16 mg tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CANDAN 8 mg tablet: each tablet contains 8 mg of Candesartan Cilexetil.
CANDAN 16 mg tablet: each tablet contains 16 mg of Candesartan Cilexetil.

Excipient with known effect
CANDAN 8 mg: each tablet contains 41.55 mg lactose monohydrate
CANDAN 16 mg: Each tablet contains 83.10 mg lactose monohydrate
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.
CANDAN 8 mg tablets are pink, biconvex, round tablet, debossed with “8” on one side and plain on other side.
CANDAN 16 mg tablets are p
ink, compact, biconvex, round, engraved on one side with code C31 and scored another side
The tablet cannot be divided into equal doses.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension in adults.<br />Treatment of adult patients with heart failure and impaired left ventricular systolic function (left ventricular<br />ejection fraction &le; 40%) when Angiotensin Converting Enzyme (ACE)-inhibitors are not tolerated or as<br />add-on therapy to ACE-inhibitors in patients with symptomatic heart failure, despite optimal therapy,<br />when mineralocorticoid receptor antagonists are not tolerated (see sections 4.2, 4.4, 4.5 and 5.1).<br />Treatment of hypertension in children and adolescents aged 6 to &lt;18 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology in hypertension<br />The recommended initial dose and usual maintenance dose of candesartan is 8 mg once daily. Most of the<br />antihypertensive effect is attained within 4 weeks. In some patients whose blood pressure is not adequately<br />controlled, the dose can be increased to 16 mg once daily and to a maximum of 32 mg once daily. Therapy<br />should be adjusted according to blood pressure response.<br />Candesartan may also be administered with other antihypertensive agents<br />Addition of hydrochlorothiazide has been shown to have an additive antihypertensive effect with various doses<br />of candesartan.<br />Elderly population<br />No initial dose adjustment is necessary in elderly patients.<br />Patients with intravascular volume depletion</p><p>An initial dose of 4 mg may be considered in patients at risk for hypotension, such as patients with possible<br />volume depletion&nbsp;<br />Renal impairment<br />The starting dose is 4 mg in patients with renal impairment, including patients on haemodialysis. The dose<br />should be titrated according to response. There is limited experience in patients with very severe or end-stage<br />renal impairment (Clcreatinine &lt; 15 ml/min)&nbsp;<br />Hepatic impairment<br />An initial dose of 4 mg once daily is recommended in patients with mild to moderate hepatic impairment. The<br />dose may be adjusted according to response. Candesartan is contraindicated in patients with severe hepatic<br />impairment and/or cholestasis&nbsp;<br />Black patients<br />The antihypertensive effect of candesartan is less pronounced in black patients than in non-black patients.<br />Consequently, up-titration of candesartan and concomitant therapy may be more frequently needed for blood<br />pressure control in black patients than non-black patients&nbsp;<br />Paediatric population<br />Children and adolescents aged 6 to &lt;18 years:<br />The recommended starting dose is 4 mg once daily.<br />&bull; For patients weighing &lt; 50 kg: In patients whose blood pressure is not adequately controlled, the dose can be<br />increased to a maximum of 8 mg once daily.</p><p>&bull; For patients weighing &ge; 50 kg: In patients whose blood pressure is not adequately controlled, the dose can be<br />increased to 8 mg once daily and then to 16 mg once daily if needed&nbsp;<br />Doses above 32 mg have not been studied in paediatric patients. Most of the antihypertensive effect is attained<br />within 4 weeks.<br />For children with possible intravascular volume depletion (e.g. patients treated with diuretics, particularly those<br />with impaired renal function). Candesartan treatment should be initiated under close medical supervision and a<br />lower starting dose than the general starting dose above should be considered<br />Candesartan has not been studied in children with glomerular filtration rate less than 30 ml/min/1.73 m2&nbsp;</p><p>Black paediatric patients<br />The antihypertensive effect of candesartan is less pronounced in black patients than in non-black patients (see<br />section 5.1).<br />Children aged below 1 year to &lt;6 years:<br />&bull; The safety and efficacy in children aged 1 to &lt;6 years of age has not been established. Currently available<br />data are described in section 5.1 but no recommendation on a posology can be made.<br />&bull; Candesartan is contraindicated in children aged below 1 year (see section 4.3).<br />Posology in heart failure<br />The usual recommended initial dose of candesartan is 4 mg once daily. Up-titration to the target dose of 32 mg<br />once daily (maximum dose) or to the highest tolerated dose is done by doubling the dose at intervals of at least<br />2 weeks (see section 4.4). Evaluation of patients with heart failure should always comprise assessment of renal<br />function including monitoring of serum creatinine and potassium. Candesartan can be administered with other<br />heart failure treatment, including ACE-inhibitors, beta-blockers, diuretics and digitalis or a combination of these<br />medicinal products. Candesartan may be co-administered with an ACE-inhibitor in patients with symptomatic<br />heart failure despite optimal standard heart failure therapy when mineralocorticoid receptor antagonists are not<br />tolerated.<br />The combination of an ACE-inhibitor, a potassium-sparing diuretic and candesartan is not recommended and<br />should be considered only after careful evaluation of the potential benefits and risks<br />Special patient populations<br />No initial dose adjustment is necessary for elderly patients or in patients with intravascular volume depletion,<br />renal impairment or mild to moderate hepatic impairment.<br />Paediatric population<br />The safety and efficacy of candesartan in children aged between birth and 18 years have not been established<br />in the treatment of heart failure. No data are available.</p><p>Method of administration<br />Oral use<br />CANDAN should be taken once daily with or without food.<br />The bioavailability of candesartan is not affected by food.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Second and third trimester of pregnancy (see sections 4.4 and 4.6).
Severe hepatic impairment and/or cholestasis.
Children aged below 1 year (see section 5.3).
The concomitant use of Candesartan Cilexetil with aliskiren-containing products is contraindicated in patients
with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)<br />There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren<br />increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure).</p><p>Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or<br />aliskiren is therefore not recommended (see sections 4.5 and 5.1).<br />If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision<br />and subject to frequent close monitoring of renal function, electrolytes and blood pressure.<br />ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic<br />nephropathy.</p><p>Renal impairment<br />As with other agents inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be<br />anticipated in susceptible patients treated with candesartan.<br />When candesartan is used in hypertensive patients with renal impairment, periodic monitoring of serum<br />potassium and creatinine levels are recommended. There is limited experience in patients with very severe or<br />end-stage renal impairment (Clcreatinine &lt;15 ml/min). In these patients candesartan should be carefully titrated<br />with thorough monitoring of blood pressure.<br />Evaluation of patients with heart failure should include periodic assessments of renal function, especially in<br />elderly patients 75 years or older, and patients with impaired renal function. During dose titration of candesartan,<br />monitoring of serum creatinine and potassium is recommended. Clinical trials in heart failure did not include<br />patients with serum creatinine &gt;265 &mu;mol/L (&gt;3 mg/dL).<br />Use in paediatric patients, including patients with renal impairment<br />Candesartan has not been studied in children with a glomerular filtration rate less than 30 ml/min/1.73 m2 (see<br />section 4.2).<br />Concomitant therapy with an ACE-inhibitor in heart failure<br />The risk of adverse reactions, especially hypotension, hyperkalaemia and decreased renal function (including<br />acute renal failure), may increase when candesartan is used in combination with an ACE-inhibitor.<br />Triple combination of an ACE-inhibitor, a mineralocorticoid receptor antagonist and candesartan are also not<br />recommended. Use of these combinations should be under specialist supervision and subject to frequent close<br />monitoring of renal function, electrolytes and blood pressure.<br />ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic<br />nephropathy.<br />Haemodialysis<br />During dialysis the blood pressure may be particularly sensitive to AT1-receptor blockade as a result of<br />reduced plasma volume and activation of the renin-angiotensin-aldosterone system. Therefore, candesartan<br />should be carefully titrated with thorough monitoring of blood pressure in patients on haemodialysis.<br />Renal artery stenosis</p><p>Medicinal products that affect the renin-angiotensin-aldosterone system, including angiotensin II receptor<br />antagonists (AIIRAs), may increase blood urea and serum creatinine in patients with bilateral renal artery<br />stenosis or stenosis of the artery to a solitary kidney.<br />Kidney transplantation<br />There is limited clinical evidence regarding candesartan use in patients who have undergone renal transplant.</p><p>Hypotension<br />Hypotension may occur during treatment with candesartan in heart failure patients. It may also occur in<br />hypertensive patients with intravascular volume depletion such as those receiving high dose diuretics. Caution<br />should be observed when initiating therapy and correction of hypovolaemia should be attempted.<br />For children with possible intravascular volume depletion (e.g. patients treated with diuretics, particularly those<br />with impaired renal function), candesartan treatment should be initiated under close medical supervision and a<br />lower starting dose should be considered (see section 4.2).<br />Anaesthesia and surgery<br />Hypotension may occur during anaesthesia and surgery in patients treated with angiotensin II antagonists due<br />to blockade of the renin-angiotensin system. Very rarely, hypotension may be severe such that it may warrant<br />the use of intravenous fluids and/or vasopressors.<br />Aortic and mitral valve stenosis (obstructive hypertrophic cardiomyopathy)<br />As with other vasodilators, special caution is indicated in patients suffering from haemodynamically relevant aortic<br />or mitral valve stenosis, or obstructive hypertrophic cardiomyopathy.<br />Primary hyperaldosteronism<br />Patients with primary hyperaldosteronism will not generally respond to antihypertensive medicinal products acting<br />through inhibition of the renin-angiotensin-aldosterone system. Therefore, the use of candesartan is not<br />recommended in this population.</p><p>Hyperkalaemia<br />Concomitant use of candesartan with potassium-sparing diuretics, potassium supplements, salt substitutes<br />containing potassium, or other medicinal products that may increase potassium levels (e.g. heparin) may lead to<br />increases in serum potassium in hypertensive patients. Monitoring of potassium should be undertaken as<br />appropriate.<br />In heart failure patients treated with candesartan, hyperkalaemia may occur. Periodic monitoring of serum<br />potassium is recommended. The combination of an ACE-inhibitor, a potassium-sparing diuretic (e.g.<br />spironolactone) and candesartan is not recommended and should be considered only after careful evaluation of<br />the potential benefits and risks.<br />General<br />In patients whose vascular tone and renal function depend predominantly on the activity of the reninangiotensinaldosterone<br />system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal<br />artery stenosis), treatment with other medicinal products that affect this system has been associated with acute<br />hypotension, azotaemia, oliguria or, rarely, acute renal failure. The possibility of similar effects cannot be<br />excluded with AIIRAs. As with any antihypertensive agent, excessive blood pressure decreases in patients with<br />ischaemic cardiopathy or ischaemic cerebrovascular disease could result in a myocardial infarction or stroke.<br />The antihypertensive effect of candesartan may be enhanced by other medicinal products with blood pressure<br />lowering properties, whether prescribed as an antihypertensive or prescribed for other indications.<br />Pregnancy<br />AIIRAs should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential,<br />patients planning pregnancy should be changed to alternative antihypertensive treatments which have an<br />established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be<br />stopped immediately, and, if appropriate, alternative therapy should be started</p><p>In post-menarche patients the possibility of pregnancy should be evaluated on a regular basis. Appropriate<br />information should be given and/or action taken to prevent the risk of exposure during pregnancy<br />CANDAN contains lactose monohydrate<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose<br />malabsorption should not take this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Compounds which have been investigated in clinical pharmacokinetic studies include hydrochlorothiazide,<br />warfarin, digoxin, oral contraceptives (i.e. ethinylestradiol/levonorgestrel), glibenclamide, nifedipine and enalapril.<br />No clinically significant pharmacokinetic interactions with these medicines have been identified.<br />Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium,<br />or other medicinal products (e.g. heparin) may increase potassium levels. Monitoring of potassium should be<br />undertaken as appropriate (see section 4.4).<br />Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant<br />administration of lithium with ACE-inhibitors. A similar effect may occur with AIIRAs. Use of candesartan with<br />lithium is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is<br />recommended.<br />When AIIRAs are administered simultaneously with non-steroidal anti-inflammatory drugs (NSAIDs) (i.e.<br />selective COX-2 inhibitors, acetylsalicylic acid (&gt;3 g/day) and non-selective NSAIDs), attenuation of the<br />antihypertensive effect may occur.<br />As with ACE-inhibitors, concomitant use of AIIRAs and NSAIDs may lead to an increased risk of worsening of<br />renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients<br />with poor pre-existing renal function. The combination should be administered with caution, especially in the<br />elderly. Patients should be adequately hydrated, and consideration should be given to monitoring renal function<br />after initiation of concomitant therapy, and periodically thereafter.<br />Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the<br />combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency<br />of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal<br />failure) compared to the use of a single RAAS-acting agent<br />Paediatric population<br />Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The use of<br />AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE-inhibitors during the first<br />trimester of pregnancy has not been conclusive; however, a small increase in risk cannot be excluded. Whilst<br />there is no controlled epidemiological data on the risk with AIIRAs, similar risks may exist for this class of drugs.<br />Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to<br />alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When<br />pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately and, if appropriate, alternative<br />therapy should be started.</p><p>Exposure to AIIRA therapy during the second and third trimesters is known to induce human foetotoxicity<br />(decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure,<br />hypotension, hyperkalaemia) (see section 5.3).<br />Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal<br />function and skull are recommended.<br />Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and<br />4.4).<br />Breast-feeding<br />Because no information is available regarding the use of candesartan during breast-feeding, candesartan is not<br />recommended and alternative treatments with better established safety profiles during breast-feeding are<br />preferable, especially while nursing a newborn or preterm infant.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of candesartan on the ability to drive and use machines have been performed. However,<br />it should be taken into account that occasionally dizziness or weariness may occur during treatment with<br />candesartan.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of hypertension<br />In controlled clinical studies adverse reactions were mild and transient. The overall incidence of adverse events<br />showed no association with dose or age. Withdrawals from treatment due to adverse events were similar with<br />candesartan cilexetil (3.1%) and placebo (3.2%).<br />In a pooled analysis of clinical trial data of hypertensive patients, adverse reactions with candesartan cilexetil<br />were defined based on an incidence of adverse events with candesartan cilexetil at least 1% higher than the<br />incidence seen with placebo. By this definition, the most commonly reported adverse reactions were<br />dizziness/vertigo, headache and respiratory infection.<br />The table below presents adverse reactions from clinical trials and post-marketing experience.<br />The frequencies used in the tables throughout this section are very common (&ge; 1/10), common (&ge;1/100</p><p>Laboratory findings<br />In general, there were no clinically important influences of candesartan on routine laboratory variables. As for<br />other inhibitors of the renin-angiotensin-aldosterone system, small decreases in haemoglobin have been seen.<br />No routine monitoring of laboratory variables is usually necessary for patients receiving candesartan. However,<br />in patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is recommended.<br />Paediatric population<br />The safety of candesartan cilexetil was monitored in 255 hypertensive children and adolescents, aged 6 to &lt;18<br />years old, during a 4-week clinical efficacy study and a 1-year open label study (see section 5.1). In nearly all<br />different system organ classes, the frequency of adverse events in children are within common/uncommon range.<br />Whilst the nature and severity of the adverse events are similar to those in adults (see the table above), the<br />frequency of all adverse events are higher in children and adolescents, particularly in:<br />&bull; Headache, dizziness and upper respiratory tract infection, are &ldquo;very common&rdquo; (i.e. &ge; 1/10) in children and<br />common (&ge; 1/100 to &lt; 1/10) in adults.<br />&bull; Cough is &ldquo;very common&rdquo; (i.e. &gt; 1/10) in children and very rare (&lt; 1/10,000) in adults.<br />&bull; Rash is &ldquo;common&rdquo; (i.e. &ge; 1/100 to &lt; 1/10) in children and &ldquo;very rare&rdquo; (&lt; 1/10,000) in adults.<br />&bull; Hyperkalaemia, hyponatraemia and abnormal liver function are uncommon (&ge; 1/1,000 to &lt; 1/100) in children<br />and very rare (&lt; 1/10,000) in adults.<br />&bull; Sinus arrhythmia, nasopharyngitis, pyrexia is &ldquo;common&rdquo; (i.e. &ge; 1/100 to &lt; 1/10) and oropharyngeal pain is &ldquo;very<br />common&rdquo; (i.e. &ge; 1/10) in children; but none are reported in adults. However, these are temporary and widespread<br />childhood illnesses.<br />The overall safety profile for candesartan cilexetil in paediatric patients does not differ significantly from the safety<br />profile in adults.</p><p>Treatment of heart failure<br />The adverse experience profile of candesartan in adult heart failure patients was consistent with the<br />pharmacology of the drug and the health status of the patients. In the CHARM clinical programme, comparing<br />candesartan in doses up to 32 mg (n=3,803) to placebo (n=3,796), 21.0% of the candesartan cilexetil group and<br />16.1% of the placebo group discontinued treatment because of adverse events. The most commonly reported<br />adverse reactions were hyperkalaemia, hypotension and renal impairment. These events were more common in<br />patients over 70 years of age, diabetics, or subjects who received other medicinal products which affect the reninangiotensin-<br />aldosterone system, in particular an ACE-inhibitor and/or spironolactone.<br />Hepatobiliary disorders Very rare Increased liver enzymes,<br />abnormal hepatic function or<br />hepatitis<br />Skin and subcutaneous tissue<br />disorders<br />Very rare Angioedema, rash, urticaria,<br />pruritus<br />Musculoskeletal and connective<br />tissue disorders<br />Very rare Back pain, arthralgia, myalgia<br />Renal and urinary disorders Very rare Renal impairment, including renal<br />failure in susceptible patients&nbsp;</p><p>Laboratory findings<br />Hyperkalaemia and renal impairment are common in patients treated with candesartan for the indication of heart<br />failure. Periodic monitoring of serum creatinine and potassium is recommended</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />Based on pharmacological considerations, the main manifestation of an overdose is likely to be symptomatic<br />hypotension and dizziness. In individual case reports of overdose (of up to 672 mg candesartan cilexetil) in an<br />adult patient recovery was uneventful.<br />Management<br />If symptomatic hypotension should occur, symptomatic treatment should be instituted, and vital signs monitored.<br />The patient should be placed supine with the legs elevated. If this is not sufficient, plasma volume should be<br />increased by infusion of, for example, isotonic saline solution. Sympathomimetic medicinal products may be<br />administered if the above-mentioned measures are not sufficient.<br />Candesartan is not removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II antagonists, plain, ATC code: C09CA06.<br />Mechanism of action<br />Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a role<br />in the pathophysiology of hypertension, heart failure and other cardiovascular disorders. It also has a role in the<br />pathogenesis of end organ hypertrophy and damage. The major physiological effects of angiotensin II, such as<br />vasoconstriction, aldosterone stimulation, regulation of salt and water homeostasis and stimulation of cell growth,<br />are mediated via the type 1 (AT1) receptor.<br />Pharmacodynamic effects<br />Candesartan cilexetil is a prodrug suitable for oral use. It is rapidly converted to the active substance,<br />candesartan, by ester hydrolysis during absorption from the gastrointestinal tract. Candesartan is an angiotensin<br />II receptor antagonist, selective for AT1 receptors, with tight binding to and slow dissociation from the receptor.<br />It has no agonist activity.<br />Candesartan does not inhibit ACE, which converts angiotensin I to angiotensin II and degrades bradykinin. There<br />is no effect on ACE and no potentiation of bradykinin or substance P. In controlled clinical trials comparing<br />candesartan with ACE-inhibitors, the incidence of cough was lower in patients receiving candesartan cilexetil.<br />Candesartan does not bind to or block other hormone receptors or ion channels known to be important in<br />cardiovascular regulation. The antagonism of the angiotensin II (AT1) receptors results in dose related increases<br />in plasma renin levels, angiotensin I and angiotensin II levels, and a decrease in plasma aldosterone<br />concentration.<br />Clinical efficacy and safety<br />Hypertension<br />In hypertension, candesartan causes a dose-dependent, long-lasting reduction in arterial blood pressure. The<br />antihypertensive action is due to decreased systemic peripheral resistance, without reflex increase in heart rate.<br />There is no indication of serious or exaggerated first dose hypotension or rebound effect after cessation of<br />treatment.<br />After administration of a single dose of candesartan cilexetil, onset of antihypertensive effect generally occurs<br />within 2 hours. With continuous treatment, most of the reduction in blood pressure with any dose is generally</p><p>attained within four weeks and is sustained during long-term treatment. According to a meta-analysis, the average<br />additional effect of a dose increase from 16 mg to 32 mg once daily was small. Taking into account the interindividual<br />variability, a more than average effect can be expected in some patients. Candesartan cilexetil once<br />daily provides effective and smooth blood pressure reduction over 24 hours, with little difference between<br />maximum and trough effects during the dosing interval. The antihypertensive effect and tolerability of<br />candesartan and losartan were compared in two randomised, double-blind studies in a total of 1,268 patients<br />with mild to moderate hypertension. The trough blood pressure reduction (systolic/diastolic) was 13.1 /10.5<br />mmHg with candesartan cilexetil 32 mg once daily and 10.0 /8.7 mmHg with losartan potassium 100 mg once<br />daily (difference in blood pressure reduction 3.1/1.8 mmHg, p&lt;0.0001/p&lt;0.0001).<br />When candesartan cilexetil is used together with hydrochlorothiazide, the reduction in blood pressure is additive.<br />An increased antihypertensive effect is also seen when candesartan cilexetil is combined with amlodipine or<br />felodipine.<br />Medicinal products that block the renin-angiotensin-aldosterone system have less pronounced antihypertensive<br />effect in black patients (usually a low-renin population) than in non-black patients. This is also the case for<br />candesartan. In an open label clinical experience trial in 5,156 patients with diastolic hypertension, the blood<br />pressure reduction during candesartan treatment was significantly less in black than non-black patients<br />(14.4/10.3 mmHg vs. 19.0/12.7 mmHg, p&lt;0.0001/p&lt;0.0001).<br />Candesartan increases renal blood flow and either has no effect on or increases glomerular filtration rate while<br />renal vascular resistance and filtration fraction are reduced. In a 3-month clinical study in hypertensive patients<br />with type 2 diabetes mellitus and microalbuminuria, antihypertensive treatment with candesartan cilexetil reduced<br />urinary albumin excretion (albumin/creatinine ratio, mean 30%, 95% confidence interval 15-42%). There is<br />currently no data on the effect of candesartan on the progression to diabetic nephropathy.<br />The effects of candesartan cilexetil 8-16 mg (mean dose 12 mg), once daily, on cardiovascular morbidity and<br />mortality was evaluated in a randomised clinical trial with 4,937 elderly patients (aged 70-89 years; 21% aged 80<br />or above) with mild to moderate hypertension followed for a mean of 3.7 years (Study on COgnition and Prognosis<br />in the Elderly). Patients received candesartan cilexetil or placebo with other antihypertensive treatment added as<br />needed. The blood pressure was reduced from 166/90 to 145/80 mmHg in the candesartan group, and from<br />167/90 to 149/82 mmHg in the control group. There was no statistically significant difference in the primary<br />endpoint, major cardiovascular events (cardiovascular mortality, non-fatal stroke and non-fatal myocardial<br />infarction). There were 26.7 events per 1000 patient-years in the candesartan group versus 30.0 events per 1000<br />patient-years in the control group (relative risk 0.89, 95% CI 0.75 to 1.06, p=0.19).<br />Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with<br />Ramipril Global Endpoint Trial) and VA NEPHRON-0 (The Veterans Affairs Nephropathy in Diabetes)) have<br />examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.<br />ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or<br />type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in<br />patients with type 2 diabetes mellitus and diabetic nephropathy.<br />These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality,<br />while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy<br />was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE<br />inhibitors and angiotensin II receptor blockers. ACE-inhibitors and angiotensin II receptor blockers should<br />therefore not be used concomitantly in patients with diabetic nephropathy.<br />ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study<br />designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II<br />receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or<br />both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death</p><p>and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse<br />events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more<br />frequently reported in the aliskiren group than in the placebo group.<br />Paediatric population - hypertension<br />The antihypertensive effects of candesartan were evaluated in hypertensive children aged 1 to &lt;6 years and 6<br />to &lt;17 years in two randomised, double-blind multicentre, 4-week dose ranging studies.<br />In children aged 1 to &lt;6 years, 93 patients, 74% of whom had renal disease, were randomised to receive an oral<br />dose of candesartan cilexetil suspension 0.05, 0.20 or 0.40 mg/kg once daily. The primary method of analysis<br />was slope of the change in systolic blood pressure (SBP) as a function of dose. SBP and diastolic blood pressure<br />(DBP) decreased 6.0/5.2 to 12.0/11.1 mmHg from baseline across the three doses of candesartan cilexetil.<br />However, since there was no placebo group, the true magnitude of blood pressure effect remains uncertain which<br />makes a conclusive assessment of benefit-risk balance difficult in this age group.<br />In children aged 6 to &lt;17 years, 240 patients were randomised to receive either placebo or low, medium, or high<br />doses of candesartan cilexetil in a ratio of 1: 2: 2: 2. For children who weighed &lt; 50 kg, the doses of candesartan<br />cilexetil were 2, 8, or 16 mg once daily. In children who weighed &gt; 50 kg, the candesartan cilexetil doses were 4,<br />16 or 32 mg once daily. Candesartan at pooled doses reduced SiSBP by 10.2 mmHg (P&lt; 0.0001) and SiDBP<br />(P=0.0029) by 6.6 mmHg, from the base line. In the placebo group, there was also a reduction of 3.7 mmHg in<br />SiSBP (p=0.0074) and 1.80 mmHg for SiDBP (p=0.0992) from the baseline. Despite the large placebo effect, all<br />individual candesartan doses (and all doses pooled) were significantly superior to placebo. Maximum response<br />in reduction of blood pressure in children below and above 50 kg was reached at 8 mg and 16 mg doses,<br />respectively and the effect plateaued after that point.<br />Of those enrolled, 47% were black patients and 29% were female; mean age +/- SD was 12.9 +/- 2.6 years. In<br />children aged 6 to &lt; 17 years there was a trend for a lesser effect on blood pressure in black patients compared<br />to non-black patients.<br />Heart failure<br />Treatment with candesartan cilexetil reduces mortality, reduces hospitalisation due to heart failure, and improves<br />symptoms in patients with left ventricular systolic dysfunction as shown in the Candesartan in Heart failure &ndash;<br />Assessment of Reduction in Mortality and morbidity (CHARM) programme. This placebo controlled, double-blind<br />study programme in chronic heart failure (CHF) patients with NYHA functional class II to IV consisted of three<br />separate studies: CHARM-Alternative (n=2,028) in patients with LVEF &le; 40% not treated with an ACE-inhibitor<br />because of intolerance (mainly due to cough, 72%), CHARMAdded (n=2,548) in patients with LVEF &le; 40% and<br />treated with an ACE-inhibitor, and CHARM Preserved (n=3,023) in patients with LVEF &gt; 40%. Patients on optimal<br />CHF therapy at baseline were randomised to placebo or candesartan cilexetil (titrated from 4 mg or 8 mg once<br />daily to 32 mg once daily or the highest tolerated dose, mean dose 24 mg) and followed for a median of 37.7<br />months. After 6 months of treatment 63% of the patients still taking candesartan cilexetil (89%) were at the target<br />dose of 32 mg.<br />In CHARM-Alternative, the composite endpoint of cardiovascular mortality or first CHF hospitalisation was<br />significantly reduced with candesartan in comparison with placebo, hazard ratio (HR) 0.77 (95% CI 0.67-0.89,<br />p&lt;0.001). This corresponds to a relative risk reduction of 23%. Of candesartan patients 33.0% (95%CI: 30.1 to<br />36.0) and of placebo patients 40.0% (95%CI: 37.0 to 43.1) experienced this endpoint, absolute difference 7.0%<br />(95%CI: 11.2 to 2.8). Fourteen patients needed to be treated for the duration of the study to prevent one patient<br />from dying of a cardiovascular event or being hospitalised for treatment of heart failure. The composite endpoint<br />of all-cause mortality or first CHF hospitalisation was also significantly reduced with candesartan, HR 0.80 (95%<br />CI 0.70-0.92, p=0.001). Of candesartan patients 36.6% (95%CI: 33.7 to 39.7) and of placebo patients 42.7%<br />(95%CI: 39.6 to 45.8) experienced this endpoint, absolute difference 6.0% (95%CI: 10.3 to 1.8). Both the mortality<br />and morbidity (CHF hospitalisation) components of these composite endpoints contributed to the favourable<br />effects of candesartan. Treatment with candesartan cilexetil resulted in improved NYHA functional class<br />(p=0.008).</p><p>In CHARM-Added, the composite endpoint of cardiovascular mortality or first CHF hospitalisation was<br />significantly reduced with candesartan in comparison with placebo, HR 0.85 (95% CI 0.75-0.96, p=0.011). This<br />corresponds to a relative risk reduction of 15%. Of candesartan patients 37.9% (95%CI: 35.2 to 40.6) and of<br />placebo patients 42.3% (95%CI: 39.6 to 45.1) experienced this endpoint, absolute difference 4.4% (95%CI: 8.2<br />to 0.6). Twenty-three patients needed to be treated for the duration of the study to prevent one patient from dying<br />of a cardiovascular event or being hospitalised for treatment of heart failure. The composite endpoint of all-cause<br />mortality or first CHF hospitalisation was also significantly reduced with candesartan, HR 0.87 (95% CI 0.78-<br />0.98, p=0.021). Of candesartan patients 42.2% (95%CI: 39.5 to 45.0) and of placebo patients 46.1% (95%CI:<br />43.4 to 48.9) experienced this endpoint, absolute difference 3.9% (95%CI: 7.8 to 0.1). Both the mortality and<br />morbidity components of these composite endpoints contributed to the favourable effects of candesartan.<br />Treatment with candesartan cilexetil resulted in improved NYHA functional class (p=0.020).<br />In CHARM-Preserved, no statistically significant reduction was achieved in the composite endpoint of<br />cardiovascular mortality or first CHF hospitalisation, HR 0.89 (95% CI 0.77-1.03, p=0.118).<br />All-cause mortality was not statistically significant when examined separately in each of the three CHARM<br />studies. However, all-cause mortality was also assessed in pooled populations, CHARM-Alternative and<br />CHARM-Added, HR 0.88 (95% CI 0.79-0.98, p=0.018) and all three studies, HR 0.91 (95% CI 0.83-1.00,<br />p=0.055).<br />The beneficial effects of candesartan were consistent irrespective of age, gender and concomitant medication.<br />Candesartan was effective also in patients taking both beta-blockers and ACE-inhibitors at the same time, and<br />the benefit was obtained whether or not patients were taking ACE-inhibitors at the target dose recommended by<br />treatment guidelines.<br />In patients with CHF and depressed left ventricular systolic function (left ventricular ejection fraction, LVEF<br />&le;40%), candesartan decreases systemic vascular resistance and pulmonary capillary wedge pressure, increases<br />plasma renin activity and angiotensin II concentration and decreases aldosterone levels.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption and distribution<br />Following oral administration, candesartan cilexetil is converted to the active substance candesartan. The<br />absolute bioavailability of candesartan is approximately 40% after an oral solution of candesartan cilexetil. The<br />relative bioavailability of the tablet formulation compared with the same oral solution is approximately 34% with<br />very little variability. The estimated absolute bioavailability of the tablet is therefore 14%. The mean peak serum<br />concentration (Cmax) is reached 3-4 hours following tablet intake. The candesartan serum concentrations<br />increase linearly with increasing doses in the therapeutic dose range. No gender related differences in the<br />pharmacokinetics of candesartan has been observed. The area under the serum concentration versus time curve<br />(AUC) of candesartan is not significantly affected by food.<br />Candesartan is highly bound to plasma protein (more than 99%). The apparent volume of distribution of<br />candesartan is 0.1 l/kg.<br />The bioavailability of candesartan is not affected by food.<br />Biotransformation and elimination<br />Candesartan is mainly eliminated unchanged via urine and bile and only to a minor extent eliminated by hepatic<br />metabolism (CYP2C9). Available interaction studies indicate no effect on CYP2C9 and CYP3A4. Based on in<br />vitro data, no interaction would be expected to occur in vivowith drugs whose metabolism is dependent on<br />cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4. The<br />terminal half-life of candesartan is approximately 9 hours. There is no accumulation following multiple doses.</p><p>Total plasma clearance of candesartan is about 0.37 ml/min/kg, with a renal clearance of about 0.19 ml/min/kg.<br />The renal elimination of candesartan is both by glomerular filtration and active tubular secretion. Following an<br />oral dose of 14C-labelled candesartan cilexetil, approximately 26% of the dose is excreted in the urine as<br />candesartan and 7% as an inactive metabolite while approximately 56% of the dose is recovered in the faeces<br />as candesartan and 10% as the inactive metabolite.<br />Pharmacokinetics in special populations<br />In the elderly (over 65 years) Cmax and AUC of candesartan are increased by approximately 50% and 80%,<br />respectively in comparison to young subjects. However, the blood pressure response and the incidence of<br />adverse events are similar after a given dose of candesartan in young and elderly patients (see section 4.2). In<br />patients with mild to moderate renal impairment Cmax and AUC of candesartan increased during repeated dosing<br />by approximately 50% and 70%, respectively, but t&frac12; was not altered, compared to patients with normal renal<br />function. The corresponding changes in patients with severe renal impairment were approximately 50% and<br />110%, respectively. The terminal t&frac12; of candesartan was approximately doubled in patients with severe renal<br />impairment. The AUC of candesartan in patients undergoing haemodialysis was similar to that in patients with<br />severe renal impairment.<br />In two studies, both including patients with mild to moderate hepatic impairment, there was an increase in the<br />mean AUC of candesartan of approximately 20% in one study and 80% in the other study (see section 4.2).<br />There is no experience in patients with severe hepatic impairment.<br />Paediatric population<br />The pharmacokinetic properties of candesartan were evaluated in hypertensive children aged 1 to &lt;6 years and<br />6 to &lt;17 years in two single dose PK studies.<br />In children aged 1 to &lt;6 years, 10 children weighing 10 to &lt;25 kg received a single dose of 0.2 mg/kg, oral<br />suspension. There was no correlation between Cmax and AUC with age or weight. No clearance data has been<br />collected; therefore, the possibility of a correlation between clearance and weight/age in this population is<br />unknown.<br />In children aged 6 to &lt;17 years, 22 children received a single dose of 16 mg tablet. There was no correlation<br />between Cmax and AUC with age. However, weight seems to significantly correlate with Cmax (p=0.012) and<br />AUC (p=0.011). No clearance data has been collected, therefore the possibility of a correlation between<br />clearance and weight/age in this population is unknown.<br />Children &gt;6 years of age had exposure similar to adults given the same dose.<br />The pharmacokinetics of candesartan cilexetil have not been investigated in paediatric patients &lt;1 year of age.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In preclinical<br />safety studies candesartan had effects on the kidneys and on red cell parameters at high doses in mice, rats,<br />dogs and monkeys. Candesartan caused a reduction of red blood cell parameters (erythrocytes, haemoglobin,<br />haematocrit). Effects on the kidneys (such as interstitial nephritis, tubular distension, basophilic tubules;<br />increased plasma concentrations of urea and creatinine) were induced by candesartan, which could be<br />secondary to the hypotensive effect leading to alterations of renal perfusion. Furthermore, candesartan induced<br />hyperplasia/hypertrophy of the juxtaglomerular cells. These changes were considered to be caused by the<br />pharmacological action of candesartan. For therapeutic doses of candesartan in humans, the<br />hyperplasia/hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.<br />In preclinical studies in normotensive neonatal and juvenile rats, candesartan caused a reduction in body weight<br />and heart weight. As in adult animals, these effects are considered to result from the pharmacological action of<br />candesartan. At the lowest dose of 10 mg/kg exposure to candesartan was between 12 and 78 times the levels<br />found in children aged 1 to &lt;6 who received candesartan cilexetil at a dose of 0.2 mg/kg and 7 to 54 times those</p><p>found in children aged 6 to &lt;17 who received candesartan cilexetil at a dose of 16 mg. As a no observed effect<br />level was not identified in these studies, the safety margin for the effects on heart weight and the clinical relevance<br />of the finding is unknown.<br />Foetotoxicity has been observed in late pregnancy (see section 4.6).<br />Data from in vitro and in vivo mutagenicity testing indicates that candesartan will not exert mutagenic or<br />clastogenic activities under conditions of clinical use. There was no evidence of carcinogenicity.<br />The renin-angiotensin-aldosterone system plays a critical role in kidney development in utero. Reninangiotensinaldosterone<br />system blockade has been shown to lead to abnormal kidney development in very young mice.<br />Administering drugs that act directly on the renin-angiotensin-aldosterone system can alter normal renal<br />development. Therefore, children aged less than 1 year should not receive candesartan cilexetil</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate, Maize Starch, Red iron oxide, Hydroxypropyl Cellulose, Polyethylene Glycol,<br />Carboxymethyl Cellulose Calcium and Magnesium Stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PVDC/ Alu blister.<br />Pack sizes:28 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Middle East Pharmaceutical Industries Co. Ltd (Avalon-Pharma)
2nd industrial City, P.O.Box 4180 Riyadh 11491, Kingdom of Saudi Arabia
Tel: 920010564, Fax: +966 (11) 2654723
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>